Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 in Relapsed/Refractory CD20+ B-cell Lymphoma
NCT04103905Phase 1Completed
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Feb 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Bejescin in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoint: Dose-limiting Toxicity at 28 days. Started Feb 2017; status: completed.
02
Drugs
Bejescin
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04103905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04103905.